Fully synthetic vaccine,in which one or multi-molecular antigens are conjugated to a synthetic carrier with well-defined chemical structure,is a new direction to develop carbohydrate-based vaccine against cancer and p...Fully synthetic vaccine,in which one or multi-molecular antigens are conjugated to a synthetic carrier with well-defined chemical structure,is a new direction to develop carbohydrate-based vaccine against cancer and pathogens.Toll like receptor(TLR)agonists with the ability to stimulate immune response have been widely investigated and been applied as build-in adjuvants to construct fully synthetic vaccines.In particular,remarkable progress has been achieved in recent years in the development of vaccines constructed with the agonists of TLRI 2,TLR2/6 and TLR4 and tumor-associated carbohydrate antigens(TACAs).These di-,tri-or multi-component vaccine candidates showed attractive immunologi-cal properties.This review highlights recent advances in developing full synthetic carbohydrate antigen based vaccines,with an emphasis on the structure-activity relationships that provide a primary basis for future vaccine design and immunotherapy developing.展开更多
基金supported by the National Natural Science Foundation of China(Nos.21472070,21602084)the project for Jiangsu Scientific and Technological Innovation Team+4 种基金the fund for Jiangsu Distinguished Professorship Programthe project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutionsthe 111 Project(No.111-2-06)the Fundamental Research Funds for the Central Universities(No.JUSRP11729)the Open Foundation of Key Laboratory of Carbohydrate Chemistry&Biotechnology Ministry of Education(No.KLCCB-KF201608)
文摘Fully synthetic vaccine,in which one or multi-molecular antigens are conjugated to a synthetic carrier with well-defined chemical structure,is a new direction to develop carbohydrate-based vaccine against cancer and pathogens.Toll like receptor(TLR)agonists with the ability to stimulate immune response have been widely investigated and been applied as build-in adjuvants to construct fully synthetic vaccines.In particular,remarkable progress has been achieved in recent years in the development of vaccines constructed with the agonists of TLRI 2,TLR2/6 and TLR4 and tumor-associated carbohydrate antigens(TACAs).These di-,tri-or multi-component vaccine candidates showed attractive immunologi-cal properties.This review highlights recent advances in developing full synthetic carbohydrate antigen based vaccines,with an emphasis on the structure-activity relationships that provide a primary basis for future vaccine design and immunotherapy developing.
